India Pharma Outlook Team | Monday, 13 April 2026
AstraZeneca Pharma has secured a key Calquence approval in India, receiving clearance from the Central Drugs Standard Control Organisation to import and distribute Acalabrutinib tablets 100 mg under the brand name Calquence.
With this nod, the company can move ahead with the commercial rollout of the drug in the country.
The approval covers the use of Acalabrutinib tablets 100 mg in combination with Venetoclax, with or without Obinutuzumab, for treating patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This Calquence approval is expected to expand treatment options for patients battling these blood cancers, offering a targeted therapy approach that is already in use globally.
Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery
AstraZeneca operates across more than 100 countries and focuses on key therapy areas including oncology, cardiovascular, renal and metabolism, and respiratory and rare diseases. The latest approval strengthens its oncology portfolio in India, a market where access to advanced cancer therapies is steadily growing.
On the financial front, the company reported a mixed performance for the third quarter of FY26. Net profit dropped 42.3% year-on-year to Rs 31.55 crore, even as net sales jumped 38.9% to Rs 615.57 crore compared to the same period last year.
Shares of the company closed 1.45% higher at Rs 8,291.50 on Friday, April 10, 2026, reflecting positive investor sentiment following the regulatory update.
